Skip to main content
Premium Trial:

Request an Annual Quote

ImmunArray Lands $10M in Private Financing

NEW YORK (GenomeWeb) – Molecular diagnostics firm ImmunArray announced that it has received a $10 million Series B investment from private investment firm Exigent Capital.

Other details of the financing were not disclosed.

The firm, which is based in Israel and Virginia, markets blood-based tests based on its iChip antibody-detecting microarray technology. So far, it has developed a six-biomarker panel for ruling out systemic lupus erythematosus and is developing tests for traumatic brain injury and immuno-oncology. The iChip platform can print proteins and peptides, short sequences of nucleotides and DNA, as well as cell surface receptors, cytokines, chemokines, and even lipid or carbohydrate-based molecules.

The funding will help the firm "accelerate and expand our commercial infrastructure, widen our reach into lupus-related products, and broaden our work into other autoimmune diseases," said CEO Donna Edmonds in a statement, adding that the money would help the firm move toward commercializing its brain injury tests.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more